ANI Pharmaceuticals, Inc. (ANIP)
NASDAQ: ANIP · Real-Time Price · USD
80.32
+0.98 (1.24%)
May 19, 2026, 4:00 PM EDT - Market closed
ANI Pharmaceuticals Stock Forecast
Stock Price Forecast
According to 8 analysts polled by S&P Global, ANI Pharmaceuticals stock has a consensus rating of "Buy" and an average price target of $109.88. The average 1-year stock price forecast is 36.80% higher than the current stock price, while the lowest is $90 (+12.05%) and the highest is $124 (+54.38%).
Price Target: $109.88 (+36.80%)
Analyst Consensus: Buy
* Price targets were last updated on Jan 16, 2026.
Analyst Ratings
The average analyst rating for ANI Pharmaceuticals stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Dec '25 | Jan '26 | Feb '26 | Mar '26 | Apr '26 | May '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 3 | 3 | 3 | 2 |
| Buy | 3 | 2 | 2 | 2 | 2 | 2 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 7 | 6 | 6 | 6 | 6 | 5 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Guggenheim | Guggenheim | Strong Buy Maintains $115 → $124 | Strong Buy | Maintains | $115 → $124 | +54.38% | Jan 16, 2026 |
| Barclays | Barclays | Buy Initiates $100 | Buy | Initiates | $100 | +24.50% | Dec 9, 2025 |
| Guggenheim | Guggenheim | Strong Buy Maintains $114 → $115 | Strong Buy | Maintains | $114 → $115 | +43.18% | Nov 10, 2025 |
| Truist Securities | Truist Securities | Hold Maintains $77 → $90 | Hold | Maintains | $77 → $90 | +12.05% | Oct 9, 2025 |
| JP Morgan | JP Morgan | Buy Maintains $95 → $115 | Buy | Maintains | $95 → $115 | +43.18% | Sep 24, 2025 |
Financial Forecast
Revenue This Year
1.07B
from 883.37M
Increased by 21.24%
Revenue Next Year
1.25B
from 1.07B
Increased by 17.09%
EPS This Year
9.26
from 3.32
Increased by 178.41%
EPS Next Year
10.80
from 9.26
Increased by 16.70%
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 1.2B | 1.4B | ||||||
| Avg | 1.1B | 1.3B | ||||||
| Low | 763.4M | 1.1B |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 31.5% | 27.6% | ||||||
| Avg | 21.2% | 17.1% | ||||||
| Low | -13.6% | 4.1% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 9.80 | 12.40 | ||||||
| Avg | 9.26 | 10.80 | ||||||
| Low | 8.63 | 9.50 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 194.7% | 34.0% | ||||||
| Avg | 178.4% | 16.7% | ||||||
| Low | 159.7% | 2.6% |
Sources: Price targets and consensus ratings provided by S&P Global Market Intelligence. Historical ratings and analyst data provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data sources.